Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 81.65
-4.25 (-4.95%)
Sep 10, 2025, 1:45 PM HKT
Shanghai Henlius Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2020 |
| 5,798 | 5,724 | 5,395 | 3,215 | 1,682 | 587.59 | Upgrade | |
Revenue Growth (YoY) | 2.79% | 6.11% | 67.82% | 91.07% | 186.34% | 546.20% | Upgrade |
Cost of Revenue | 1,412 | 1,540 | 1,476 | 844.62 | 522.75 | 182.12 | Upgrade |
Gross Profit | 4,386 | 4,185 | 3,919 | 2,370 | 1,160 | 405.47 | Upgrade |
Selling, General & Admin | 2,401 | 2,288 | 2,138 | 1,403 | 800.87 | 436.29 | Upgrade |
Research & Development | 1,138 | 1,035 | 1,119 | 1,395 | 1,024 | 894.14 | Upgrade |
Operating Expenses | 3,537 | 3,318 | 3,266 | 2,999 | 1,825 | 1,330 | Upgrade |
Operating Income | 848.47 | 866.5 | 652.95 | -628.53 | -665.25 | -924.95 | Upgrade |
Interest Expense | -114.43 | -122.89 | -110.54 | -105.67 | -84.82 | -43.71 | Upgrade |
Interest & Investment Income | 20.88 | 21.7 | 8.15 | 3.57 | 2.69 | 7.4 | Upgrade |
Currency Exchange Gain (Loss) | 4.57 | 8.14 | -1.42 | 32.92 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 84.4 | 72.43 | 20.44 | 202.97 | -209.36 | -32.29 | Upgrade |
EBT Excluding Unusual Items | 843.9 | 845.88 | 569.58 | -494.73 | -956.74 | -993.54 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -199.15 | - | - | Upgrade |
Pretax Income | 843.9 | 845.88 | 569.58 | -693.89 | -956.74 | -993.54 | Upgrade |
Income Tax Expense | 19.6 | 25.41 | 23.56 | 1.37 | 27.31 | - | Upgrade |
Earnings From Continuing Operations | 824.3 | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade |
Net Income | 824.3 | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade |
Net Income to Common | 824.3 | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade |
Net Income Growth | 19.06% | 50.26% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 543 | 543 | 543 | 542 | 539 | 530 | Upgrade |
Shares Outstanding (Diluted) | 543 | 543 | 543 | 542 | 539 | 530 | Upgrade |
Shares Change (YoY) | -0.00% | 0.02% | 0.25% | 0.59% | 1.75% | 6.52% | Upgrade |
EPS (Basic) | 1.52 | 1.51 | 1.01 | -1.28 | -1.83 | -1.88 | Upgrade |
EPS (Diluted) | 1.52 | 1.51 | 1.00 | -1.28 | -1.83 | -1.88 | Upgrade |
EPS Growth | 19.43% | 50.96% | - | - | - | - | Upgrade |
Free Cash Flow | - | 1,078 | 574.25 | 396.65 | -370.04 | -1,167 | Upgrade |
Free Cash Flow Per Share | - | 1.98 | 1.06 | 0.73 | -0.69 | -2.20 | Upgrade |
Gross Margin | 75.64% | 73.10% | 72.64% | 73.73% | 68.93% | 69.01% | Upgrade |
Operating Margin | 14.63% | 15.14% | 12.10% | -19.55% | -39.54% | -157.41% | Upgrade |
Profit Margin | 14.22% | 14.33% | 10.12% | -21.63% | -58.49% | -169.09% | Upgrade |
Free Cash Flow Margin | - | 18.83% | 10.64% | 12.34% | -21.99% | -198.54% | Upgrade |
EBITDA | 1,153 | 1,162 | 932.58 | -419.93 | -518.3 | -831.47 | Upgrade |
EBITDA Margin | 19.89% | 20.29% | 17.29% | -13.06% | -30.80% | -141.50% | Upgrade |
D&A For EBITDA | 304.65 | 295.29 | 279.63 | 208.6 | 146.95 | 93.49 | Upgrade |
EBIT | 848.47 | 866.5 | 652.95 | -628.53 | -665.25 | -924.95 | Upgrade |
EBIT Margin | 14.63% | 15.14% | 12.10% | -19.55% | -39.54% | -157.41% | Upgrade |
Effective Tax Rate | 2.32% | 3.00% | 4.14% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.